DiaMedica Inc. Stock Toronto S.E.
Equities
DMA
CA25253T1075
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 181M 132M |
---|---|---|---|---|---|
Net income 2024 * | -37M -26.96M | Net income 2025 * | -47M -34.24M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.89
x | P/E ratio 2025 * |
-4.18
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.96% |
Latest transcript on DiaMedica Inc.
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 05-03-31 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 18-03-31 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 23-05-29 |
Tanya Lewis
BRD | Director/Board Member | 53 | 23-02-28 |
James Parsons
BRD | Director/Board Member | 58 | 10-10-19 |
1st Jan change | Capi. | |
---|---|---|
+2.93% | 108B | |
-0.15% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- DMAC Stock
- DMA Stock